Clinical pharmacy specialists in thoracic oncology discuss how frontline immunotherapy regimens are chosen in non-small cell lung cancer, weighing clinical data, payer requirements, and institutional habits, and examine testing delays, histology-specific care, subcutaneous formulations, reimbursement clarity, immune-related adverse events, and the pharmacist's role in practice change.
In this Pharmacy Times Practice Pearls series, expert pharmacists Anthony Perissinotti, Jessica Lewis-Gonzalez, and Deidra Smith discuss key updates and clinical insights related to systemic mastocytosis. The discussion focuses on disease biology and diagnosis, symptom management and treatment strategies across the indolent-to-advanced disease spectrum, and the pharmacist's critical role in dosing, monitoring, patient education, and improving access to care.
In this Pharmacy Times Practice Pearls series, expert panelists discuss key updates and clinical insights related to relapsed/refractory multiple myeloma (RRMM). The discussion covers the biological rationale for targeting B-cell maturation antigen (BCMA), the mechanisms of action differentiating chimeric antigen receptor T-cell (CAR T-Cell) therapies, bispecific antibodies, and antibody-drug conjugates (ADCs), and the clinical evidence supporting earlier use of these agents. Additional topics include individualized treatment sequencing, patient selection, ocular adverse event management, community-based administration and access barriers, Risk Evaluation and Mitigation Strategy (REMS) program requirements, adverse event management across all three drug classes, and the pharmacist's essential role in patient education, operational infrastructure, and real-world evidence generation.
In this Pharmacy Times Practice Pearls series, oncology pharmacists Zahra Mahmoudjafari, James Davis, and Kristen Boykin share real-world perspectives on the implementation of bispecific antibody therapy in multiple myeloma, drawing on their collective experience across academic medical centers and large-scale community oncology practices. The panelists examine the most pressing operational challenges in bispecific antibody programs while providing their perspectives on navigating the evolving treatment landscape.
Expert clinicians discuss key data updates from ESMO 2025 and their main takeaways for clinical practice. Considerations for both academic and community settings are also discussed.
Ryan Haumschild, PharmD, MS, MBA, CPEL; Patrick Boland, MD, and Ashley Finamore, PharmD, BCOP discuss how to optimize third-line treatment decisions in metastatic colorectal cancer by balancing efficacy data from trials like SUNLIGHT (which showed improved survival with trifluridine/tipiracil plus bevacizumab) with patient-specific factors including quality of life, tolerability profiles, pill burden considerations, and individualized shared decision-making approaches that prioritize what patients value most in their treatment journey.
Ryan Haumschild, PharmD, MS, MBA, CPEL; Sandy Sallam, PharmD, BCACP, CDCES; and Aparna Goel, MD, examine the evolving landscape of primary biliary cholangitis management, from initial diagnosis through first-line ursodeoxycholic acid therapy to emerging second-line treatments including seladelpar, elafibranor, and obeticholic acid, with particular focus on efficacy data, safety profiles, treatment transitions, and strategies for optimizing patient outcomes while navigating regulatory and access challenges.
Arun Jesudian, MD, moderates an expert panel on hepatic encephalopathy (HE), discussing treatment goals, first-line pharmacotherapy, and the crucial role of medication adherence in preventing relapse among HE patients.
To optimize patient safety, health care experts explore questions on assessment tools, monitoring strategies, specialty dosage forms, waste reduction, interdisciplinary collaboration, and responsible opioid prescribing practices.
Experts discuss the implementation, challenges, and safety measures of bispecific antibodies in lymphoma care, emphasizing multidisciplinary collaboration and patient access while navigating toxicity management.
A panel of experts delve into the multifaceted world of hemophilia A, exploring its impact, therapies, real-world data, and the role of specialty pharmacists in patient care by analyzing recent clinical insights, and share best practices for optimal patient outcomes.
Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding disease burden and treatment management of indolent relapse and aggressive relapse multiple myeloma.
Medical experts discuss several topics pertaining to the evolving treatments in HR+/HER2- advanced breast cancer, including unmet needs and the integral role of pharmacists in patient care.
Pharmacy specialists discuss quality initiatives for myeloproliferative neoplasms, highlighting the importance of patient-specific, informative care in polycythemia vera, essential thrombocythemia, and myelofibrosis.
Experts in gynecologic oncology review the use of PARP inhibitors in ovarian cancer with a primary focus of these agents as a frontline maintenance strategy.
A panel of experts discuss several topics pertaining to best practices and the challenges in regard to prophylaxis in hemophilia A, including the role of prophylaxis, prophylactic therapy options, outpatient care factors, and economic considerations.
Madeline Camejo, PharmD, MS, Michael Epshteyn, PharmD, MSM, and Estela Trimino, PharmD, BCPS, provide insights into the best practices implemented within their institutions by health-system pharmacy to address challenges brought on by COVID-19 related to infection control, treatment, and vaccine rollout.
